JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression KL Owen, NK Brockwell, BS Parker Cancers 11 (12), 2002, 2019 | 468 | 2019 |
A niche-dependent myeloid transcriptome signature defines dormant myeloma cells WH Khoo, G Ledergor, A Weiner, DL Roden, RL Terry, MM McDonald, ... Blood, The Journal of the American Society of Hematology 134 (1), 30-43, 2019 | 119 | 2019 |
Prostate cancer cell‐intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone KL Owen, LJ Gearing, DJ Zanker, NK Brockwell, WH Khoo, DL Roden, ... EMBO reports 21 (6), e50162, 2020 | 69 | 2020 |
Neoadjuvant interferons: Critical for effective PD-1–based Immunotherapy in TNBC NK Brockwell, KL Owen, D Zanker, A Spurling, J Rautela, ... Cancer immunology research 5 (10), 871-884, 2017 | 69 | 2017 |
Intratumoral administration of the Toll‐like receptor 7/8 agonist 3M‐052 enhances interferon‐driven tumor immunogenicity and suppresses metastatic spread in preclinical triple … DJ Zanker, AJ Spurling, NK Brockwell, KL Owen, JM Zakhour, T Robinson, ... Clinical & translational immunology 9 (9), e1177, 2020 | 33 | 2020 |
Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC NK Brockwell, J Rautela, KL Owen, LJ Gearing, S Deb, K Harvey, ... NPJ Precision Oncology 3 (1), 21, 2019 | 28 | 2019 |
Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis KL Owen, BS Parker Molecular immunology 110, 57-68, 2019 | 26 | 2019 |
AlphaBet: combination of radium-223 and [177Lu] Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol) L Kostos, JP Buteau, T Yeung, JD Iulio, J Xie, A Cardin, KY Chin, ... Frontiers in medicine 9, 1059122, 2022 | 18 | 2022 |
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer DJ Zanker, KL Owen, N Baschuk, AJ Spurling, BS Parker Cancer Immunology, Immunotherapy 70 (8), 2125-2138, 2021 | 17 | 2021 |
Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC. Cancer Immunol Res. 2017; 5: 871–884. doi: 10.1158/2326-6066 NK Brockwell, KL Owen, D Zanker, A Spurling, J Rautela, ... CIR-17-0150.[Abstract][CrossRef][Google Scholar], 0 | 9 | |
JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel). 2019; 11: 2002 KL Owen, NK Brockwell, BS Parker | 8 | |
Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer M Alizadeh-Ghodsi, KL Owen, SL Townley, D Zanker, SPG Rollin, ... Cancer research communications 2 (7), 706-724, 2022 | 4 | 2022 |
AlphaBet: Combination of Radium-and [Lu] Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial L Kostos, JP Buteau, T Yeung, J Di Iulio, J Xie, A Cardin, KY Chin, ... Targeted alpha particle therapy in oncology, 2023 | | 2023 |
AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [177Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer … LK Kostos, JP Buteau, T Yeung, S Xie, J Di Iulio, A Cardin, K Owen, ... Journal of Clinical Oncology 41 (6_suppl), TPS280-TPS280, 2023 | | 2023 |
Current Perspectives on Cancer Immunotherapy in Bone KL Owen, NK Brockwell, BS Parker Academic Press, 2020 | | 2020 |
The role of tumour-intrinsic signalling in regulating dormancy and prostate cancer progression in bone KL Owen La Trobe, 2019 | | 2019 |